Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 127,725

Document Document Title
WO/2017/186934A1
The invention relates to dipeptidyl peptidase-4 inhibitors, including saxagliptin and sitagliptin, for use in the topical eye treatment and/or prevention of retinal neurodegenerative diseases, in particulardiabetic retinopathyand its ass...  
WO/2017/185899A1
A composition, and a crocins active site extracted from Gardenia jasminoides Ellis, mainly comprising the following ingredients: crocetin di-β-D-gentiobioside, crocetin-β-D-glucopyranosyl-β-D-gentiobioside, crocetin di-β-D-glucopyran...  
WO/2017/188365A1
A medicine for preventing and/or treating multiple sclerosis, particularly pain such as neuropathic pain associated with multiple sclerosis and the like, said medicine containing, as an active ingredient, a compound having an antagonisti...  
WO/2017/189951A1
A method for evaluating a subject's risk of developing glaucoma, or having glaucoma, or having glaucoma that will progress in severity comprising determining from a biological sample from a subject whether the patient has a mitochondrial...  
WO/2017/188260A1
In some embodiments, a composition of matter includes aripiprazole, a metal selected from the group consisting of magnesium, zinc, sodium, lithium, iron, or alloys thereof, or combinations thereof and a copper salt selected from the grou...  
WO/2017/187338A4
The present invention relates to pharmaceutically acceptable complex formulation comprising complexes of Lumacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/189375A1
A chewing gum composition comprising cannabinoids or derivatives thereof and nicotine in the form of nicotine polacrilex is provided. The chewing gum composition is formulated to provide rapid and controlled release of cannabinoids and n...  
WO/2017/187338A1
The present invention relates to pharmaceutically acceptable complex formulation comprising complexes of Lumacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/187340A1
The invention is directed to a pharmaceutical combination composition comprising stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lum...  
WO/2017/187336A1
The present invention relates to pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/185250A1
Provided in the present application is a peptide containing the amino acid sequence YEKLTTLDTGGV (SEQ ID NO:1) or a functional variant thereof, the peptide being an active peptide for treating central nervous system injury. Also provided...  
WO/2017/181585A1
The present invention relates to the technical field of medicine, and specifically relates to a PUMA inhibitor, a method for preparation thereof, and a use thereof. The PUMA inhibitor is the compound as shown in (I) or a pharmaceutically...  
WO/2017/181790A1
A neutron capture therapy system for eliminating an amyloid β-protein plaque. The system comprises: a neutron capture therapy device and a compound comprising 10B, wherein the compound can specifically bind to an amyloid β-protein plaq...  
WO/2017/185061A1
The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.  
WO/2017/181811A1
Disclosed are an opctahydroanthracene compound as represented by formula (I) or (II), a preparation method for same, and uses of same, which provides great therapeutic effects for tumors and neurodegenerative diseases and is prepared mai...  
WO/2017/185073A1
The present invention provides methods and compositions for improving episodic memory and treating dementia.  
WO/2017/184871A1
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions...  
WO/2017/185083A1
Methods useful for treating X-linked adrenoleukodystrophy are provided.  
WO/2017/183734A1
Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt the...  
WO/2017/185010A1
The present invention relates to compositions and methods of treating lysosomal storage diseases and methods of using trehalose.  
WO/2017/182464A1
The present invention relates to compounds of formula (I); which are capable of inhibiting the 11-beta-hydroxysteroid dehydrogenase type 1 (11- beta-HSD1), to processes for preparing these compounds, to pharmaceutical compositions compri...  
WO/2017/184871A9
The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions...  
WO/2017/185087A1
Methods useful for treating X-linked adrenoleukodystrophy are provided.  
WO/2017/183736A1
Dopamine-producing neural precursor cells are produced by: producing a cell population containing Corin and/or Lrtm1 positive cells via steps (1) and (2) as will be shown below; collecting the Corin and/or Lrtm1 positive cells from the c...  
WO/2017/183970A1
The invention concerns nutritional compositions comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ALA weight ratio in the range of 0.1 –12 that have a beneficial effect on preventing early life stress induced decline...  
WO/2017/182688A1
The present invention relates to a powdered composition obtained from an extract of saffron stigmas, characterized in that it comprises from 0.03% to 1 % dry weight of safranal; and at least 3.48 % dry weight of crocins, encompassing the...  
WO/2017/181791A1
Provided is an application of a compound comprising 10B for preparing a pharmaceutical product specifically binding an amyloid β-protein. After the pharmaceutical product specifically binding the amyloid β-protein binds the amyloid β-...  
WO/2017/182945A1
The present disclosure relates to fluorescent compounds with large Stokes' shift. This disclosure also relates to the, production methods and use of said fluorescent compounds for cellular labelling and in vivo imaging for use in medicin...  
WO/2017/183956A1
The invention concerns nutritional compositions comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 that have a beneficial effect on preventing early life stress induced decline...  
WO/2017/181849A1
The present invention relates to an indoleamine 2,3-dioxygenase inhibitor having the structure of formula (I), a preparation method therefor, and an application. The IDO inhibitor is an N'-hydroxyl-N-phenylformamidine derivative, has hig...  
WO/2017/185027A1
Disclosed are methods and compositions for treating a subject having a neurological disorder such as major depressive disorder (MDD). The methods and compositions may be utilized in order to inhibit trafficking of hyperpolarization-activ...  
WO/2017/181898A1
Provided are nine multi-target polypeptides of an opioid and a neuropeptide FF receptor, where an amino acid is replaced on the basis of opioid peptide biphalin- and NPFF-based chimeric peptide BN-9, and acquired are the multi-target pol...  
WO/2017/184658A1
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.  
WO/2017/178510A1
The present invention relates to arylamide derivatives having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit,of the voltage-gated calcium channel and the µ-opioid receptor, to processes o...  
WO/2017/178344A1
This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar1 ...  
WO/2017/179225A1
Provided is a composition which can effectively suppress or improve physical hypofunction observed with age or physical dysfunction occurring with age, or mental hypofunction observed with age or mental dysfunction occurring with age, sa...  
WO/2017/179354A1
The purpose of the present invention is to provide a composition that is effective for maintaining, enhancing and improving recognition functions, etc. According to the present invention, a composition for maintaining, enhancing and/or i...  
WO/2017/178663A1
The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam.  
WO/2017/178807A1
The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a furth...  
WO/2017/181004A1
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a ph...  
WO/2017/178339A1
This invention relates to compounds of formula (I) a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R...  
WO/2017/178499A1
The present invention relates to inhibitors of glucosylceramide degradation, to pharmaceutical compositions containing same and to the use of same in the treatment of diseases of the motor units, such as amyotrophic lateral sclerosis.  
WO/2017/180589A1
The present disclosure provides compounds of Formula I and/or Formula II, or pharmaceutically acceptable salts thereof: wherein D is deuterium and each deuterium has deuterium enrichment of no less than about 10%, compositions containing...  
WO/2017/180025A3
The invention relates to the field of pharmacology and may be used for the prevention and treatment of diseases related to the occurrence of glutamate stress. The aim of the present invention consists in creating an accessible neuroprote...  
WO/2017/178511A1
The invention relates to a cell population comprising a hematopoietic stem cell (HSC) and a hematopoietic progenitor cell (HPC), for use in the treatment of Parkinsonism in a subject, and to pharmaceutical compositions and kits for use i...  
WO/2017/179646A1
A cell secreted-type amylospheroid (ASPD)-like structure, a drug and vaccine using the same, and a production method thereof are provided. This production method involves a step in which cells expressing amyloid precursor protein (APP), ...  
WO/2017/180781A1
Disclosed are methods and compositions for the treatment of autism spectrum disorder, related disorders and symptoms of such disorders, comprising co-administration of an oxytocin peptide and magnesium ions. Co-administration of an oxyto...  
WO/2017/180064A1
The invention relates to medicine and veterinary applications, in particular, as a means for effective control of acute and/or chronic pain, and may be used in emergency medicine for the treatment of acute and/or chronic pain, including ...  
WO/2017/177261A1
Pharmaceutical preparations comprising cannabinoid resins encapsulated in liposomes are provided. The preparations are characterised by particular molar ratios of carboxyl containing cannabinoids to their decarboxylated counterparts. Als...  
WO/2017/177999A1
According to the invention, melatonin or melatonergic substances are used for treating an REM sleep behaviour disorder in a human. According to the invention, an unspecified dose of melatonin is taken in a previously specified time windo...  

Matches 351 - 400 out of 127,725